Announcements
The Active Cancer Immunotherapy OBI-822, has been granted by AEMPS of Spain to proceed to Phase III Clinical Trial
1.Date of occurrence of the event: 2022/01/25 2.New drug name or code: Active Cancer Immunotherapy OBI-822 (Adagloxad Simolenin) 3.Indication: OBI-822 is a therapeutic cancer vaccine classified as active cancer immunotherapy. …
The Active Cancer Immunotherapy OBI-822, has been granted by DIGEMID of Peru to proceed to Phase III clinical trial
1.Date of occurrence of the event: 2021/12/18 2.New drug name or code: Active cancer immunotherapy OBI-822 (Adagloxad Simolenin) 3.Indication: OBI-822 is a therapeutic cancer vaccine classified as active cancer immunotherapy. …
OBI has filed the application for a Phase II clinical trial for OBI-833, an active cancer immunotherapy, to TFDA
1.Date of occurrence of the event: 2021/12/15 2.New drug name or code: Active cancer immunotherapy, OBI-833 3.Indication: OBI-833 is a therapeutic cancer vaccine against Globo H, which is classified as …
OBI in-licensed “anti-Trop2 antibody” exclusive rights from Biosion
1.Date of occurrence of the event: 2021/12/08 2.Counterparty to the contract or commitment: Biosion, Inc. 3.Relationship with the Company: None 4.Starting and ending dates (or rescission date) of the contract …
The Active Cancer Immunotherapy OBI-822, has been granted by COFEPRIS of Mexico to proceed to Phase III Human Clinical Study
1.Date of occurrence of the event: 2021/12/03 2.New drug name or code: Active cancer immunotherapy OBI-822 (Adagloxad Simolenin) 3.Indication: OBI-822 is a therapeutic cancer vaccine classified as active cancer immunotherapy. …
Announcement on behalf of subsidiary, OBIGEN, that OBI-858 completes its Phase I and demonstrates good safety, proceeding to Phase II as planned
1.Date of occurrence of the event:2021/11/30 2.New drug name or code:Novel Botulinum Neurotoxin, OBI-858 3.Indication:OBI-858, an in-house developed new botulinum neurotoxin (BoNT) product, is planned for aesthetic and therapeutic uses. …
OBI’s BOD resolved to in-license a preclinical project from a biotech company specialized in novel cancer therapies
1.Date of occurrence of the event: 2021/11/26 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4.Reciprocal shareholding ratios: No applicable 5.Cause …
Announcement of the resolution of the Board of Directors of the Company to issue common shares through cash capital increase
1.Date of the board of directors resolution: 2021/11/26 2.Source of capital increase funds: Issue common shares through cash capital increase 3.Number of shares issued (not including those distributed to employees …
Supplementary statements on news article
1.Date of occurrence of the event: 2021/11/12 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): head office 4.Reciprocal shareholding ratios: Not applicable 5.Name …
Intellectual property rights licensing of OBI’s cancer therapies in China has been granted by MOEAIC
1. Date of occurrence of the event: 2021/11/11 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. Reciprocal shareholding …